CAR与TCR之争:谁更胜一筹?
本文是一篇综述,围绕嵌合抗原受体T细胞(CAR-T)疗法在B细胞血液恶性肿瘤中的显著疗效与多数患者输注后仍复发的问题,从敏感性、信号通路、杀伤机制和性能等方面对CAR与内源性T细胞受体(TCR)进行平行比较,并讨论现有发现如何为提升CAR-T疗效提供新见解。
要点
- CAR-T细胞疗法在治疗B细胞血液恶性肿瘤方面具有显著疗效和突破。
- 多数接受CAR-T细胞治疗的患者在输注后仍会复发。
- CAR与内源性TCR在敏感性、信号通路、杀伤机制和性能方面的异同尚未完全明确。
核心结论
- 综述从多个方面对CAR与TCR进行平行比较,并讨论现有发现如何为提升CAR-T细胞疗法疗效提供新见解。
研究设计与样本
- 综述,讨论CAR与TCR在敏感性、信号通路、杀伤机制和性能等方面的平行比较。
主要发现
- CAR-T细胞疗法在治疗B细胞血液恶性肿瘤方面具有显著疗效和突破。
- 多数接受CAR-T细胞治疗的患者在输注后仍会复发。
- CAR来源于TCR复合体及与T细胞活化相关的共刺激分子。
- CAR与内源性TCR在敏感性、信号通路、杀伤机制和性能方面的异同尚未完全明确。
局限性
- CAR与内源性TCR在敏感性、信号通路、杀伤机制和性能方面的异同尚未完全明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Even though CAR-T cell therapy has outstanding clinical successes, most treated patients still relapse after infusion. CARs are derived from the T cell receptor (TCR) complex and co-stimulatory molecules associated with T cell activation; however, the similarities and differences between CARs and endogenous TCRs regarding their sensitivity, signaling pathway, killing mechanisms, and performance are still not fully understood. In this review, we discuss the parallel comparisons between CARs and TCRs from various aspects and how these current findings might provide novel insights and contribute to improvement of CAR-T cell therapy efficacy.
引用
- Yun K, Siegler EL, Kenderian SS, et al. Who wins the combat, CAR or TCR? Leukemia. 2023. PMID: 37626090. doi:10.1038/s41375-023-01976-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。